论文部分内容阅读
目的:在消化性溃疡患者的治疗过程中应用奥美拉唑联合康复新液治疗,分析其临床疗效和安全性。方法:收集我院自2013年1月至2015年1月期间所收治的66例消化性溃疡患者,将其依据计算机表法均分为研究组与对照组,每组患者例数为33例。在治疗对照组患者时应用奥美拉唑治疗,在治疗观察组患者时应用奥美拉唑联合康复新液治疗,将两组患者行不同疗法的临床疗效和安全性进行对比分析。结果:经对应性治疗后,研究组患者的总有效率显著优于对照组,差异显著且P值小于0.05,存在统计学意义;研究组患者的不良反应率与对照组差异不明显,P值大于0.05,不存在统计学意义。结论:在消化性溃疡患者的治疗过程中应用奥美拉唑联合康复新液治疗的临床疗效较高,具有临床推广意义。
Objective: To treat patients with peptic ulcer during the treatment of omeprazole combined with rehabilitation new solution, analysis of its clinical efficacy and safety. Methods: A total of 66 patients with peptic ulcer admitted from January 2013 to January 2015 in our hospital were divided into study group and control group according to the computerized table method. The number of patients in each group was 33 cases. Omeprazole was used in the treatment of patients in the control group, while omeprazole combined with Fufangxin liquid was used in the treatment of the observation group. The clinical efficacy and safety of different therapies were compared between the two groups. Results: After the corresponding treatment, the total effective rate of the study group was significantly better than the control group, the difference was significant and the P value was less than 0.05, statistically significant; the adverse reaction rate of study group patients with the control group was not significant, P value Above 0.05, there is no statistical significance. Conclusion: The clinical efficacy of omeprazole combined with Fufuxin solution in the treatment of patients with peptic ulcer is high, which has clinical significance.